

Natco Pharma Limited Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243 CIN : L24230TG1981PLC003201, www.natcopharma.co.in

21st February 2025

Corporate Relationship Department M/s. BSE Limited Dalal Street, Fort <u>Mumbai 400001</u> The Manager - Listing M/s. National Stock Exchange of India Ltd "Exchange Plaza", Bandra – Kurla Complex Bandra (E) Mumbai 400051

Scrip Code: NATCOPHARM

Dear Sir/Madam,

Scrip Code: 524816

Sub:- Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the above cited subject, we would like to inform you that the Company has received orders dated 19th February, 2025 from Additional Director of Income Tax (International Taxation)-2, Hyderabad. The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31st December, 2024 are as under:

SI.	Particulars	Information
No.		
1	Name of the Authority	Additional Director of Income Tax (International Taxation)-2, Hyderabad
2	Nature and details of the action(s) taken or order(s) passed	Order u/s 201 of the Income-tax Act, 1961 passed by the ADIT (INT TAXN)-2, HYD imposing a demand of INR 99,88,470.00 & INR 1,40,91,612.00 towards TDS and interest for AY 18-19 & AY 19-20 respectively
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	Order dated 19-02-2025 made available on the TRACES portal on 21-02-2025.
4	Details of the violation(s) / contravention (s) committed or alleged to be committed	The authorities have passed order levying TDS on certain international payments on contention that the income earned by the foreign parties would be taxable in India.
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	Based on assessment of facts and prevailing law, the Company is of the view that the demand levied is arbitrary and unjustified.
		The Company will file necessary appeal with the appellate authority in this regard.
		There is no material impact on the Company's financials or operations due to the said order.

This is for your information and records. Thanking you,

Yours faithfully, For NATCO Pharma Limited

Ch. Venkat Ramesh Company Secretary & Compliance Officer